Neuroleptic Malignant Syndrome With Risperidone
Authors:
- Gary M. LevinGLGary M. Levin
- Andrea L. LazowickALAndrea L. Lazowick
- Hannah S. PowellHPHannah S. Powell
- 1 April 1996
- journal article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 16 (2) , 192-193
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Risperidone-induced neuroleptic malignant syndrome in young patientThe Lancet, 1994
- Risperidone-induced neuroleptic malignant syndromeThe Lancet, 1994
- Neuroleptic malignant syndrome associated with the use of risperidone, an atypical antipsychotic agentHuman Psychopharmacology: Clinical and Experimental, 1994
- RisperidonePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1994
- Neuroleptic malignant syndromeMedical Clinics of North America, 1993
- The Treatment of Neuroleptic Malignant Syndrome are Dantrolene and Bromocriptine Useful Adjuncts to Supportive Care?The British Journal of Psychiatry, 1991
- Epidemiology of Neuroleptic Malignant SyndromePsychiatric Annals, 1991
- The Neuroleptic Malignant Syndrome, So-calledThe British Journal of Psychiatry, 1987